Vetoquinol Global is a family-owned French company that specializes in animal health. Founded in 1933, it has evolved from a regional pharmaceutical laboratory into a global leader in veterinary pharmaceuticals, operating in around 100 countries. The company is headquartered in Lure, France.

Vetoquinol focuses on the development, manufacturing, and marketing of veterinary drugs and non-medicinal products for both companion animals, such as dogs and cats, and livestock, including cattle and pigs. Its product range includes pharmaceuticals like antibiotics and anti-inflammatory drugs, nutraceuticals for nutritional support, and hygiene products to maintain animal health. The company invests significantly in research and development, dedicating about 7.5% of its revenue to innovation, which helps expand its product pipeline.

With revenues of approximately 436 million in 2022 and projections of 500 million for 2023, Vetoquinol is publicly traded on Euronext Paris. The company maintains strong relationships with veterinarians, farmers, and pet owners, reflecting its commitment to improving animal health and welfare.